Montelukast for Postinfectious Cough

Phase 2

• Conditions: Cough
• Interventions: Drug: Montelukast

• Registration Number: NCT02352545
• Lead Sponsor: Beijing Chao Yang Hospital

Brief Summary

Cough is a common symptom of respiratory medicine clinic patients, which has complex etiology and wide-ranging. Cough is usually divided into three categories by time: acute cough, subacute cough and chronic cough. Subacute has a 3\~8 weeks course of disease. Its main etiology is postinfectious cough, which is mostly secondary to viral infection.Considering its overexpression in postinfectious patient, Cysteinyl leukotriene (CysLTs) plays a role in gathering eosinophils to respiratory. The level of FENO has a significant correlation with inflammatory airway eosinophils. While CysLTs overexpressed in vivo, the level of FENO may increase. Montelukast, as CysLTs-receptor-1 antagonists， plays a role of controlling airway inflammation and decrease airway high activity by suppressing the biological activity of CysLTs. It is effective in theory to therapy sub-acute cough by Montelukast, to short the course and to relieve cough symptoms as soon as possible. The aim is to research whether FENO can be used as a biomarker to optimized treatment regimen of sub-acute cough.

Detailed Description

Patients in electrical treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.

Study Timeline

• Study Start: 2014-08
• Status Verified: 2015-01
• Study First Submitted: 2015-01-16
• Study First Submitted QC: 2015-01-28
• Last Update Submitted: 2015-01-28
• Study First Posted: 2015-02-02
• Last Update Posted: 2015-02-02
• Primary Completion: 2015-08
• Study Completion: 2015-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Cough is the main or only clinical symptom and was persistent for 3-8 weeks

• Chest X-ray reveals no noticeable pathological changes

  • 18 year old, regardless of gender and ethical background

• Not taking angiotensin-converting enzyme inhibitor

• Patients must join the programme voluntarily and are able to attend examination and follow-up sessions

Exclusion Criteria

• Patients diagnosed with allergic rhinitis, chronic nasosinusitis or bacterial respiratory tract infections
• Patients diagnosed with severe reportorial disease of other severe systemic disease
• Patients who are allergic to any drugs to be tested
• Patients who are non-cooperative during examination sessions or other steps of the trial
• Patients who are not able to or refuse to sign consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Experimental: Montelukast	Montelukast	Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.

Primary Outcome Measures

Name	Time	Method
Change in Leicester Cough Questionnaire(LCQ) total and domain scores at 10 days post randomisation	10 days

Secondary Outcome Measures

Name	Time	Method
cough visual analogue scale scores post randomisation(area under the curve)	10 days
Change in Leicester Cough Questionnaire(LCQ) physical,psychological and social domain scores at 10 days post randomisation	10 days

Trial Locations

Locations (1)

Kewu Huang; 🇨🇳 China, Beijing, China